News & Updates

Consolidation treatment with the PD-L1 antibody durvalumab following concurrent chemoradiotherapy significantly prolonged overall (OS) and progression-free survival (PFS) in patients with limited-stage small-cell lung cancer (SCLC), as shown in the interim analysis of the phase III ADRIATIC trial.

Use of neoadjuvant daromun in addition to surgery is safe and provides survival benefits in patients with resectable, locally advanced melanoma, results of the PIVOTAL study have shown.

Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.

An exosome-based liquid biopsy showed favourable signals for noninvasive, early detection of pancreatic ductal adenocarcinoma (PDAC) in a prospective study.

An investigational blood-based test performs satisfactorily for the early detection of colorectal cancer (CRC), having met all prespecified primary endpoints in the large PREEMPT CRC trial.

Several symptoms of individuals with fibromyalgia (FM), including fatigue and sleep disturbance, have significant impacts on their daily life, and the prevalence of such symptoms may vary depending on demographic categories and disability status, according to a study.